Metoclopramide for Acute Upper GI Bleeding

Launched by KING CHULALONGKORN MEMORIAL HOSPITAL · Feb 23, 2021

Keywords

ClinConnect Summary

* Double-blind, Double centers, RCT
* All endoscopists at two participating sites attend the pre-study meeting for standardization of protocol and scoring system.
* Eligible patients were randomly assigned to either metoclopramide or placebo group in a 1:1 conceal allocation according to a computer-generated randomization list with block randomization in size of four.
* Assigned treatment was kept in opaque sealed envelopes.
* Before EGD, the patients had adequate resuscitation to maintain stable hemodynamics(SBP ≥ 90 mmHg and/or HR \< 100 bpm) and blood transfusion to reach Hb\> 7g/dL and ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \>= 18 years
• • 2. Active upper GI bleeding ( defined as fresh or bright red hematemesis within 24hr. or presented of blood via NG aspiration )
• • 3. Underwent upper GI endoscopy within 12hr
• • 4. Informed consent obtained
• Exclusion Criteria:
• • 1. Known allergy of metoclopramide
• • 2. History of gastric or duodenal surgery
• • 3. Known case esophageal, gastric or duodenal cancer
• • 4. Diagnosed with advanced HIV infection (defined as CD4 cell count \<200 cells/mm3 or WHO clinical stage 3 or 4)
• • 5. Pregnancy or lactating
• • 6. NG lavage was done with solution \> 50 ml.